DENTAL-MONITORING
16.3.2020 19:13:09 CET | Business Wire | Press release
Dental Monitoring tele dentistry solutions allow dental professionals to connect with their patients remotely and in a HIPAA compliant manner. Our unique technology enables dentists and orthodontists to assess, monitor treatment, and communicate with their patients as much as needed, even when they are at home.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200316005750/en/
Given the unprecedented situation we are facing worldwide, and with patient access to practices becoming more difficult, Dental Monitoring’s priorities have shifted to supporting all dental professionals whoever and wherever they are, to continue the care of their patients, as well as ensuring the continuity of their practices. Our current solutions use the full extent of our AI engine, and complete onboarding for practices can often take a few weeks to integrate fully. Therefore we have decided to refocus our company priorities to launch immediately two new “Light ” versions of our existing solutions. These new versions will be simpler and more immediate to implement for these times - rapid on-boarding and roll-out to all patients:
Photo Monitoring Light :
Simplified at-home monitoring platform with instant two-way communication with patients.
Capturing pictures of the mouth through the DM App allowing doctors to :
- Evaluate remotely their patients' current oral situation or treatment progress as if they were in the practice
- Have two way communication and guidance between doctor and patient
- Send annotated pictures directly via the patient App so patients can better understand their doctor’s guidance.
Photo Monitoring Light will also enable the clinical team to request an immediate DM scan when a patient requests immediate feedback, so that the doctor can better evaluate the patient’s situation and advise accordingly.
To implement Photo Monitoring Light: please visit https://dental-monitoring.com/maintain-patient-care/
SmileMate Virtual Consultation:
Remote assessment of new and existing patients.
All patient calls can be pre-qualified remotely using the SmileMate assessment tool directly through doctors practice websites.
The process is simple:
Step 1- The patient clicks on the widget on the doctor’s website, creates a profile and takes five intra-oral pictures on their smartphone (no need to download an app or use cheek retractors)
Step 2- A comprehensive customized report and treatment option is automatically generated by our AI engine and sent to the doctor
Step 3- Doctors qualify the patient’s needs on their SmileMate portal
Step 4- Doctors customize and share the report with the patient with advice or a booking link.
To implement SmileMate Virtual Consultation please visit: https://dental-monitoring.com/maintain-patient-care/
Fast-Track Accelerated On-Boarding.
Photo Monitoring Light and SmileMate Virtual Consultation are ready for use in minutes after doctors and their teams have performed our free fast-track accelerated training. Implementing fast-track onboarding into dental practices is simplified through our new streamlined process, which is done 100% remotely through webinars by our customer support team.
Call us or visit: https://dental-monitoring.com/maintain-patient-care/
to book a time slot for our next training session.
Opening up a dedicated 24/7 hotline to answer any questions or needs during the pandemic.
Our priority has always been our customers and their patients. Over the next few months, we will be solely focused on delivering solutions that can help doctors maintain the expert care they provide to their patients. To that extent, and during the pandemic, we will maximize accessibility to our solutions by reducing our price on these new solutions by 50% :
- Photo Monitoring Light will be accessible for US$3 per month/patient monitored
- For SmileMate Virtual Consultation will be at US$150/month for 50 unique patient scans
We have also directed our worldwide sales force to focus 100% on Customer Service - working side by side with doctors to help treat their patients remotely.
About Dental Monitoring
(www.dental-monitoring.com
)
Founded in 2015 by Philippe Salah, Dental Monitoring is the first AI-based company to target dental professionals’ needs. The DM software suite is designed to address the needs of dental professionals all along the patient journey: before treatment to increase the patient’s engagement, during treatment to improve the quality of care provided by the doctor, and after treatment to ensure the stability of the treatment outcome. The company currently operates in Europe, the United States, and Asia-Pacific. It employs a team of about 250 employees across its 5 offices located in Paris, Austin, London, Hong Kong, and Sydney.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200316005750/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings30.8.2026 14:23:00 CEST | Press release
–Late-Breaking Prespecified Subgroup Analysis of HELIOS-B Demonstrates that Vutrisiran Provided Consistent Clinical Benefit Across All-Cause Mortality and Recurrent Cardiovascular Events in Patients With or Without Tafamidis Use at Baseline ––Additional Post Hoc Analyses Highlight Positive Impact of Vutrisiran in Addressing the Multisystemic Manifestations of ATTR-CM ––Pooled Analysis Across Four Positive Phase 3 Studies of Vutrisiran and Patisiran Shows Consistent Treatment Effect Across Sexes ––New Subgroup Analysis from KARDIA-3 Phase 2 Study of Zilebesiran Highlights Potential to Provide Enhanced Blood Pressure Control – Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new data at the European Society of Cardiology (ESC) Congress 2026 demonstrating the strength of RNAi-powered silencing for cardiovascular disease. The findings further reinforce the clinical profile of AMVUTTRA® (vutrisiran) across transthyretin amyloidosis (ATTR)
New Auction Record Set as Falcon Sells for AED 1.5 Million at ADIHEX 202629.8.2026 23:54:00 CEST | Press release
Qarmousha Pure Ultra White falcon sells for AED 1.5 million at the Abu Dhabi International Hunting and Equestrian Exhibition 2026 (ADIHEX) falcon auction Under the patronage of His Highness Sheikh Hamdan bin Zayed Al Nahyan, Ruler’s Representative in Al Dhafra Region and Chairman of the Emirates Falconers’ Club, the fifth auction held as part of the 23rd edition of the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX) 2026 attracted remarkable turnout, culminating in the sale of a Qarmousha Pure Ultra White falcon for AED 1.5 million (USD 408,000). The sale marks the highest price achieved at any auction during this year’s edition of the exhibition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260829032621/en/ Qarmousha Pure Ultra White (Photo: AETOSWire) This forms part of the largest auction programme in the exhibition’s history, held under the theme “A Legacy of Pride,” organised by ADNEC Group, a Modon
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 00:40:00 CEST | Press release
MIMRYLO, a First-in-Class Medicine with a Unique Mechanism of Action, is Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV)MIMRYLO Has Been Shown to Maintain Hematocrit Control, the Primary Treatment Goal in PV, as Well as Reduce Phlebotomy Burden and Improve FatigueApproval Supported by Phase 3 VERIFY Results Showing 76.9% of Patients Achieved Clinical Response During Weeks 20-32 Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the tot
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom